CDXS - Codexis, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
CDXS price evolution
CDXS
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $20.17 | $59.63 | $66.7 | |
| Short term investments | $54.54 | $27.4 | -$0.07 | |
| Net receivables | $16.54 | $12.39 | $11.7 | $19.18 |
| Inventory | $2.1 | $2.23 | $2.44 | $2.69 |
| Total current assets | $112.9 | $91.4 | $107.95 | $93.47 |
| Long term investments | $9.7 | $9.7 | $9.7 | |
| Property, plant & equipment | $24.04 | $25.54 | $27.03 | $28.62 |
| Goodwill & intangible assets | $2.46 | $2.46 | $2.46 | |
| Total noncurrent assets | $40.61 | $41.61 | $43.09 | |
| Total investments | $64.24 | $37.1 | $9.63 | |
| Total assets | $148.18 | $132.01 | $149.56 | $136.56 |
| Current liabilities | ||||
| Accounts payable | $4.21 | $3.69 | $3.46 | $5.95 |
| Deferred revenue | $10 | $10.49 | $10.76 | |
| Short long term debt | $3.98 | $3.88 | $3.78 | |
| Total current liabilities | $35.13 | $30.54 | $29.08 | $35.83 |
| Long term debt | $28.63 | $28.36 | $39.33 | $12.24 |
| Total noncurrent liabilities | $40.02 | $41.21 | $14.12 | |
| Total debt | $42.53 | $43.21 | $16.02 | |
| Total liabilities | $74.78 | $70.56 | $70.29 | $49.95 |
| Shareholders' equity | ||||
| Retained earnings | -$552.43 | -$531.79 | -$509.04 | -$497.53 |
| Other shareholder equity | $0.13 | -$0.02 | -$0.02 | |
| Total shareholder equity | $61.45 | $79.27 | $86.61 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $66.7 | $116.03 | $118.89 | $150.82 |
| Short term investments | -$0.07 | -$0.16 | -$0.42 | $0.93 |
| Net receivables | $19.18 | $40.87 | $33.51 | $24.84 |
| Inventory | $2.69 | $2.03 | $1.16 | $0.96 |
| Total current assets | $93.47 | $162.89 | $161.89 | $184.42 |
| Long term investments | $9.7 | $20.51 | $14 | $1.45 |
| Property, plant & equipment | $28.62 | $61.88 | $65.46 | $31.18 |
| Goodwill & intangible assets | $2.46 | $3.24 | $3.24 | $3.24 |
| Total noncurrent assets | $43.09 | $87.5 | $84.5 | $37.22 |
| Total investments | $9.63 | $20.35 | $13.59 | $2.38 |
| Total assets | $136.56 | $250.39 | $246.38 | $221.65 |
| Current liabilities | ||||
| Accounts payable | $5.95 | $3.25 | $3 | $2.97 |
| Deferred revenue | $10.76 | $30.61 | $6.33 | $4.79 |
| Short long term debt | $3.78 | $5.36 | $4.09 | $2.63 |
| Total current liabilities | $35.83 | $49.07 | $33.37 | $24.98 |
| Long term debt | $12.24 | $38.28 | $43.56 | $22.32 |
| Total noncurrent liabilities | $14.12 | $56.53 | $48.62 | $26.56 |
| Total debt | $16.02 | $43.64 | $47.65 | $24.95 |
| Total liabilities | $49.95 | $105.6 | $81.99 | $51.54 |
| Shareholders' equity | ||||
| Retained earnings | -$497.53 | -$421.29 | -$387.7 | -$366.42 |
| Other shareholder equity | ||||
| Total shareholder equity | $86.61 | $144.8 | $164.39 | $170.1 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.83 | $7.98 | $17.07 | $26.56 |
| Cost of revenue | $3.46 | $4.86 | $2.86 | |
| Gross Profit | $8.52 | $4.52 | $12.22 | $23.7 |
| Operating activities | ||||
| Research & development | $11.41 | $11.25 | $11.23 | |
| Selling, general & administrative | $15.67 | $12.86 | $12.18 | |
| Total operating expenses | $25.07 | $27.25 | $24.11 | $23.42 |
| Operating income | -$22.73 | -$11.89 | $0.28 | |
| Income from continuing operations | ||||
| EBIT | -$21.76 | -$11.49 | -$7.16 | |
| Income tax expense | $0.01 | $0.01 | $0.01 | $0.04 |
| Interest expense | $0.85 | $0.98 | ||
| Net income | ||||
| Net income | -$20.64 | -$22.75 | -$11.51 | -$7.19 |
| Income (for common shares) | -$22.75 | -$11.51 | -$7.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $70.14 | $138.59 | $104.75 | $69.06 |
| Cost of revenue | $12.81 | $38.03 | $22.21 | $13.74 |
| Gross Profit | $57.33 | $100.56 | $82.55 | $55.31 |
| Operating activities | ||||
| Research & development | $58.88 | $80.1 | $55.92 | $44.19 |
| Selling, general & administrative | $53.25 | $52.17 | $49.32 | $35.05 |
| Total operating expenses | $125.4 | $135.44 | $105.24 | $79.23 |
| Operating income | -$68.07 | -$34.88 | -$22.7 | -$23.92 |
| Income from continuing operations | ||||
| EBIT | -$76.17 | -$33.32 | -$21.09 | -$23.67 |
| Income tax expense | $0.07 | $0.28 | $0.19 | $0.34 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$76.24 | -$33.59 | -$21.28 | -$24.01 |
| Income (for common shares) | -$76.24 | -$33.59 | -$21.28 | -$24.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$22.75 | -$11.51 | -$7.19 | |
| Operating activities | ||||
| Depreciation | $2.05 | $2.02 | $1.97 | |
| Business acquisitions & disposals | -$1.19 | |||
| Stock-based compensation | $4.68 | $3.17 | $2.16 | |
| Total cash flows from operations | -$12.17 | -$7.79 | -$11.04 | |
| Investing activities | ||||
| Capital expenditures | -$0.39 | -$1.12 | $1.1 | |
| Investments | -$26.7 | -$27.44 | $1.19 | |
| Total cash flows from investing | -$54.12 | -$27.09 | -$28.56 | $1.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.39 | $0.22 | ||
| Net borrowings | -$0.18 | $29.06 | ||
| Total cash flows from financing | $59.39 | -$0.2 | $29.28 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$27.67 | -$39.45 | -$7.07 | -$9.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$76.24 | -$33.59 | -$21.28 | -$24.01 |
| Operating activities | ||||
| Depreciation | $9.92 | $10.25 | $5.95 | $4.55 |
| Business acquisitions & disposals | -$1.19 | -$5.3 | -$7.63 | |
| Stock-based compensation | $9.97 | $14.53 | $11.59 | $7.73 |
| Total cash flows from operations | -$52.64 | $11.28 | -$14.27 | -$16.46 |
| Investing activities | ||||
| Capital expenditures | -$3.67 | -$8.28 | -$13.79 | -$3.75 |
| Investments | -$2 | |||
| Total cash flows from investing | -$4.86 | -$13.58 | -$21.42 | -$5.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.57 | $0.91 | $4.97 | $87.57 |
| Net borrowings | -$0.06 | |||
| Total cash flows from financing | $8.17 | -$0.57 | $3.77 | $80.81 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$49.33 | -$2.87 | -$31.92 | $58.6 |
News
Fundamentals
| Market cap | $160.31M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 81.38M |
| Revenue | $64.45M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$62.09M |
| Revenue Q/Q | 38.33% |
| Revenue Y/Y | -12.86% |
| P/E ratio | -2.58 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.49 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.76 |
|---|---|
| ROA | -43.86% |
| ROE | N/A |
| Debt/Equity | 0.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.21 |
| Quick ratio | 3.15 |